Translate page

Presentations from the 19th John Goldman Conference on CML

We are pleased to make available a couple presentations recorded during the scientific sessions at the 19th Annual John Goldman Conference on CML in Estoril. Presentations currently featured include response to front-line imatinib treatment in children and adolescents and factors affecting adherence in CML and ways to improvement. More presentations will be made available over the next couple of weeks.

VEP Suttorp

Response to front-line imatinib treatment in children and adolescents with CML -
data from a large pediatric cohort
Meinolf Suttorp, University Hospital Dresden, Germany 

  • Study design
  • Hematological findings at diagnosis
  • Imatinib dose, monitoring, and methods
  • Cytogenetic response in patients with CML-CP
  • Molecular response in patients with CML-CP
  • Impairment of growth in pediatric patients on imatinib
  • Probability of PFS in patients diagnosed in CML-CP
  • Summary

Marc Delord






Burden of CML in China and India:
The rising incidence and prevalance of the disease
Marc Delord, Université Paris Diderot, France 

  • Basic CML epidemiology
  • India and China demographics
  • Incidence of CML in India and China
  • Prevalence of CML in India and China
  • Conclusions and perspectives

Jana Pelouchova






Factors influencing adherence in CML and ways to improvement:
Results from a patient-driven survey of 2,546 patients in 63 countries
Jana Pelouchová, European Cancer Patient Coalition (ECPC), Czech Republic 

  • CML Advocates Network: Patients creating scientific evidence
  • Why this study?
  • Where are we now?
  • Truly global research: 2,546 patients from 63 countries
  • Validated adherence scales to classify patients into levels of adherence
  • Results on adherence levels
  • What can we do to drive adherence?
  • Conclusions


 We are very grateful for the support of Brandcast media to produce this web stream
VEP Soverini







Mutation Screening:
What is standard of care today and the role of new modalities
Simona Soverini, University of Bologna, Italy 

  • BCR-ABL kinase domain (KD) mutation for optimal patient management
  • When to perform BCR-ABL KD mutation analysis
  • How to perform BCR-ABL KD mutation analysis
  • BCR-ABL KD mutation screening: key issues
  • Next-generation sequencing (NGS): applications
  • NGS for routine BCR-ABL mutatation testing: when?
  • NGS for routine BCR-ABL mutation screening: hurdles
  • Conclusions


David Yeung 3Devendra HiwaseAgnes YONG w labcoat1

Dr David Yeung        Dr Devendra Hiwase     Dr Agnes Yong



Session 2: TKI resistance / failure

  • When frontline therapy fails 
    (Dr David Yeung)
  • CML - beyond chronic phase
    (Dr Devendra Hiwase)
  • Allograft - still a role in CML?
    (Dr Agnes Yong)



VEP Mahon 





Stopping TKI therapy in Chronic Myeloid Leukemia
Francois-Xavier Mahon, Hospital University of Bordeaux, France 

  • What are the criteria for stopping treatment?
  • What is the definition of molecular relapse triggering re-treatment?
  • Is it safe to stop treatment?
  • Can we cure CML?